ArticleMolecular neurobiology2014
Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-β/β-catenin and STAT3 signaling pathways.
Article in Molecular neurobiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Medicinal potential of embelin and its nanoformulations: An update on the molecular mechanism and various applications.Iranian journal of basic medical sciences · 2024Review
- Effect of embelin on inhibition of cell growth and induction of apoptosis in Acanthamoeba castellanii.Archives of microbiology · 2023Article
- Reviewing the Traditional/Modern Uses, Phytochemistry, Essential Oils/Extracts and Pharmacology ofAntioxidants (Basel, Switzerland) · 2022Review
- Expression pattern analysis and drug differential sensitivity of cancer-associated fibroblasts in triple-negative breast cancer.Translational oncology · 2021Article
- IL-22 produced by Th22 cells aggravates atherosclerosis development in ApoEJournal of cellular and molecular medicine · 2020Article
- Embelin as a Novel Inhibitor of PKC in the Prevention of Platelet Activation and Thrombus Formation.Journal of clinical medicine · 2019Article
- miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock.Cell death & disease · 2019Article
- Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses.Journal of neuroinflammation · 2019Article
- Embelin attenuates adipogenesis and lipogenesis through activating canonical Wnt signaling and inhibits high-fat diet-induced obesity.International journal of obesity (2005) · 2017Article
- Oxidized Hemoglobin Is Antigenic and Immunogenic in Lupus.Frontiers in immunology · 2017Article
- Plant Derived Phytocompound, Embelin in CNS Disorders: A Systematic Review.Frontiers in pharmacology · 2017Review
- Plumbagin protects liver against fulminant hepatic failure and chronic liver fibrosis via inhibiting inflammation and collagen production.Oncotarget · 2016Article
- Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.Molecular neurobiology · 2016Article
- Translational utility of experimental autoimmune encephalomyelitis: recent developments.Journal of inflammation research · 2015Review
- MicroRNA-214 induces dendritic cell switching from tolerance to immunity by targeting β-Catenin signaling.International journal of clinical and experimental pathology · 2015Article
- Article
- ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.Journal of molecular medicine (Berlin, Germany) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone, EB) has been shown to inhibit the X-linked inhibitor of apoptosis protein and various inflammatory pathways. Although different molecular mechanisms have been described for the potent antitumor activities of EB, its potential effect on inflammatory and immune-mediated diseases such as multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) remains unclear. In this study, we demonstrated that EB suppressed human CD14(+) monocyte-derived dendritic cell (DC) differentiation, maturation, and endocytosis and further inhibited the stimulatory function of mature DCs on allogeneic T cell proliferation in vitro. In addition, EB blocked the DC-derived expression of the Th1 cell-polarizing cytokines interferon-γ and interleukin (IL)-12 and the Th17 cell-polarizing cytokines IL-6 and IL-23. In vivo administration of EB led to a reduction in the EAE clinical score, in central nervous system inflammation, and in demyelination. Furthermore, EB also suppressed inflammatory Th1 and Th17 cells in EAE, at least partially, through the promotion of transforming growth factor-beta and β-catenin expression and inhibition of signal transducer and activator of transcription 3 signaling pathways in DCs. These data suggest that EB has potent anti-inflammatory and immunosuppressive properties and is a potential therapeutic drug for MS and other autoimmune inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.